FERNANDA SPADOTTO BAPTISTA
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/57 - Laboratório de Fisiologia Obstétrica, Hospital das Clínicas, Faculdade de Medicina
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/57 - Laboratório de Fisiologia Obstétrica, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Expert Recommendations on Monkeypox (MPX) in Pregnancy, Postpartum and Lactating Women(2022) MATTAR, Rosiane; NETO, Antonio Rodrigues Braga; LUZ, Adriana Gomes; HATANAKA, Alan; ZACONETA, Alberto; GUAZZELLI, Cristina Aparecida Falbo; TRAINA, Evelyn; BAPTISTA, Fernanda Spadotto; OSANAN, Gabriel; DUARTE, Geraldo; RAMOS, Jose Geraldo Lopes; OPPERMANN, Maria Lucia; FRANCISCO, Rossana Pulcineli Vieira; CARDOSO, Sigrid Maria Loureiro de Queiroz; QUINTANA, Silvana Maria; SUN, Sue Yazaki; BORGES, Vera Therezinha Medeiros
- Risk factors for oxygen requirement in hospitalized pregnant and postpartum women with COVID-19(2022) BAPTISTA, Fernanda Spadotto; PAGANOTI, Cristiane Freitas; GOMEZ, Ursula Trovato; PERES, Stela Verzinhasse; MALBOUISSON, Luiz Marcelo; BRIZOT, Maria de Lourdes; FRANCISCO, Rossana Pulcineli VieiraObjective: To identify risk factors for Oxygen (O-2) needs in pregnant and postpartum women with COVID-19. Methods: Prospective cohort involving pregnant women hospitalized with COVID-19 from April to October 2020. The oxygen need was analyzed regarding risk factors: demographic characteristics, clinical and laboratory parameters at hospital admission, and chest Computer Tomography (CT) findings. Poisson univariate analysis was used to estimate the Relative Risk (RR) and 95% Confidence Intervals. Results: 145 patients, 80 who used and 65 who did not use O-2, were included. Body mass index >= 30, smoking, and chronic hypertension increased the risk of O-2 need by 1.86 (95% CI 1.10-3.21), 1.57 (95% CI 1.16-2.12), and 1.46 (95% CI 1.09-1.95), respectively. Patients who were hospitalized for COVID-19 and for obstetric reasons had 8.24 (95% CI 2.8-24.29) and 3.44 (95% CI 1.05-11.31) times more use of O-2 than those admitted for childbirth and abortion. Respiratory rate >= 24 breaths/min and O-2 saturation < 95% presented RR for O-2 requirements of 2.55 (1.82-3.56) and 1.68 (95% CI 1.27-2.20), respectively. Ground Glass (GG) < 50% and with GG >= 50%, the risk of O-2 use were respectively 3.41-fold and 5.33-fold higher than in patients who haven't viral pneumonia on CT. The combination of C-reactive protein >= 21 mg/L, hemoglobin < 11.0 g/dL, and lymphopenia < 1500 mm(3) on hospital admission increased the risk of O-2 use by 4.97-times. Conclusions: In obstetric patients, clinical history, laboratory, clinical and radiological parameters at admission were identified as a risk for O-2 need, selecting the population with the greatest chance of worsening.
- Impact of SARS-CoV-2 on pregnancy and neonatal outcomes: An open prospective study of pregnant women in Brazil(2022) GOMEZ, Ursula Trovato; FRANCISCO, Rossana Pulcineli Vieira; BAPTISTA, Fernanda Spadotto; GIBELLI, Maria Augusta B. C.; IBIDI, Silvia Maria; CARVALHO, Werther Brunow de; PAGANOTI, Cristiane de Freitas; SABINO, Ester Cerdeira; SILVA, Lea Campos de Oliveira da; JAENISCH, Thomas; MAYAUD, Philippe; BRIZOT, Maria de LourdesObjectives: To determine the incidence and risk of adverse obstetric and neonatal outcomes according to SARSCoV-2 infection severity in pregnant women. Method: Open prospective study of pregnant women tested for SARS-CoV-2 by serological and molecular assays during pregnancy or delivery in two hospitals in Sao Paulo, Brazil from April 12, 2020, to February 28, 2021. Five groups were considered for analysis: C0, negative COVID-19 results and no COVID-19 symptoms; C1, positive COVID-19 results, and no symptoms; C2, positive COVID-19 results with mild symptoms; C3, positive COVID-19 results with moderate symptoms; and C4, positive COVID-19 results with severe symptoms. The association between obstetric and neonatal outcomes and COVID-19 severity was determined using multivariate analysis. Results: 734 eligible pregnant women were enrolled as follows: C0 (n = 357), C1 (n = 127), C2 (n = 174), C3 (n = 37), and C4 (n = 39). The following pregnancy and neonatal outcomes were associated with severe COVID19: oligohydramnios (adjusted Odds Ratio [aOR] = 6.18; 95% CI 1.87-20.39), fetal distress (aOR = 4.01; 95% Confidence Interval [CI] 1.84-8.75), preterm birth (aOR = 5.51; 95% CI 1.47-20.61), longer hospital stay (aOR = 1.66; 95% CI 1.36-2.02), and admission to the neonatal intensive care unit (aOR = 19.36; 95% CI, 5.8663.99). All maternal (n = 6, 15.4%, p < 0.001) and neonatal (n = 5, 12.5%, p < 0.001) deaths and most fetal deaths (n = 4, 9.8%, p < 0.001) occurred in C4 group. Moderate COVID-19 was associated with oligohydramnios (aOR = 6.23; 95% CI 1.93-20.13) , preterm birth (aOR = 3.60; 95% CI 1.45-9.27). Mild COVID-19 was asso-ciated with oligohydramnios (aOR = 3.77; 95% CI 1.56-9.07). Conclusion: Adverse pregnancy and neonatal outcomes were associated with maternal symptomatic COVID-19 sta-tus , risk increased with disease severity.